Select a medication above to begin.
Litfulo
ritlecitinib
Black Box Warnings .
Serious Infections
incr. risk of serious bacterial, fungal, viral, and opportunistic infection, including TB, leading to hospitalization or death; serious appendicitis, COVID-19 infection, including pneumonia, sepsis and multi-dermatomal herpes zoster reported with ritlecitinib; Interrupt tx if serious infection occurs, and tx infection until resolved before resuming ritlecitinib; avoid use in patients with active, serious infection, including active TB; screen for latent TB infection and initiate anti-TB tx before ritlecitinib tx start; weigh risk/benefit before tx in patients with chronic or recurrent infection, serious or opportunistic infection history, underlying conditions predisposing to infections, and in patients exposed to TB, including residing or traveling to areas of endemic TB or mycoses; monitor closely for active TB infection during tx, including patients with baseline negative latent TB screening
Mortality
higher rate of mortality, including sudden cardiovascular death, observed in RA patients 50 yo and older with at least 1 cardiovascular risk factor treated with an oral JAK inhibitor (tofacitinib) vs. TNF blockers in a large, randomized, post-marketing study; ritlecitinib not approved for use in RA patients
Malignancies
malignancies, including non-melanoma skin CA observed in patients treated with ritlecitinib; lymphoma and other malignancies observed in patients treated with oral JAK inhibitors for inflammatory conditions; higher rate of malignancies, excluding non-melanoma skin CA, observed in RA patients treated with an oral JAK inhibitor (tofacitinib) vs. TNF blockers; incr. risk in current or past smokers; weigh risk/benefit in patients with known malignancy, patients who develop a malignancy during tx, or patients who are current or past smokers; periodic skin exams recommended for patients with incr. risk
Major Adverse Cardiovascular Events
higher rate of major adverse cardiovascular events, including cardiovascular death, non-fatal MI, and non-fatal stroke, observed in RA patients 50 yo and older with at least 1 cardiovascular risk factor treated with an oral JAK inhibitor (tofacitinib) vs. TNF blockers; incr. risk in current or past smokers; weigh risk/benefit in patients who are current or past smokers or patients with other cardiovascular risk factors; D/C ritlecitinib in patients that experienced MI or stroke
Thrombosis
thromboembolic events observed with ritlecitinib; higher rate of thrombosis observed in RA patients 50 yo and older with at least 1 cardiovascular risk factor treated with an oral JAK inhibitor (tofacitinib) vs. TNF blockers; avoid ritlecitinib in patients at incr. thrombosis risk; D/C ritlecitinib and promptly evaluate patients with thrombosis symptoms
Adult Dosing .
Dosage forms: CAP: 50 mg
alopecia areata, severe
- [50 mg PO qd]
- Info: do not crush, split, chew cap; interrupt tx if lymphocytes <500; D/C if Plt <50,000
renal dosing
- [see below]
- renal impairment: no adjustment
- HD/PD: not defined
hepatic dosing
- [see below]
- Child-Pugh Class A or B: no adjustment; Child-Pugh Class C: not defined
Peds Dosing .
- Dosage forms: CAP: 50 mg
alopecia areata, severe
- [12 yo and older]
- Dose: 50 mg PO qd; Info: do not crush, split, chew cap; interrupt tx if lymphocytes <500; D/C if Plt <50,000
renal dosing
- [see below]
- renal impairment: no adjustment
- HD/PD: not defined
hepatic dosing
- [see below]
- Child-Pugh Class A or B: no adjustment; Child-Pugh Class C: not defined
Contraindications / Cautions .
- hypersensitivity to drug or ingredient
- infection, active
- TB infection, active
- thrombosis risk
- HBV infection
- HCV infection
- lymphocytes <500
- Plt <100,000
- avoid: breastfeeding during tx and x14h after D/C
- caution: patients >65 yo
- caution: infection risk
- caution: infection, chronic
- caution: infection, recurrent
- caution: infection history, serious
- caution: opportunistic infection history
- caution: TB infection, latent
- caution: TB infection risk
- caution: residents of area with endemic TB
- caution: travelers in area with endemic TB
- caution: residents of area with endemic mycosis
- caution: travelers in area with endemic mycosis
- caution: herpes zoster history
- caution: HBV infection history
- caution: malignancy
- caution: cardiovascular disease
- caution: cardiovascular disease risk
- caution: smokers
- caution: past smokers
Drug Interactions .
Overview
ritlecitinib
JAK inhibitor
- CYP3A4 substrate
- CYP1A2 inhibitor, weak
- CYP3A4 inhibitor, weak
- immunomodulatory effects
- thrombogenic effects
Contraindicated
- adenovirus vaccine, live
- BCG live intravesical
- chikungunya vaccine, live
- cholera vaccine, live
- cisapride
- dengue vaccine, live
- eliglustat
- fezolinetant
- influenza nasal vaccine, live
- measles/mumps/rubella vaccine, live
- rotavirus vaccine, live
- smallpox vaccine, live
- talimogene laherparepvec
- typhoid vaccine, live
- varicella vaccine, live
- yellow fever vaccine, live
Avoid/Use Alternative
- abatacept
- abrocitinib
- adalimumab
- afamitresgene autoleucel
- aldesleukin
- alemtuzumab
- alprazolam
- anakinra
- anifrolumab
- anti-thymocyte globulin
- apalutamide
- axicabtagene ciloleucel
- azathioprine
- baricitinib
- basiliximab
- belatacept
- belimumab
- blinatumomab
- brentuximab vedotin
- brexucabtagene autoleucel
- brodalumab
- butalbital
- canakinumab
- carbamazepine
- certolizumab pegol
- ciltacabtagene autoleucel
- cladribine oral
- codeine
- colchicine
- crovalimab
- cyclosporine
- daratumumab
- delgocitinib topical
- deucravacitinib
- deuruxolitinib
- dinutuximab
- dupilumab
- eculizumab
- efgartigimod alfa
- elotuzumab
- elranatamab
- emapalumab
- encorafenib
- enzalutamide
- epcoritamab
- etanercept
- etrasimod
- everolimus
- fedratinib
- fosphenytoin
- gemtuzumab ozogamicin
- glofitamab
- golimumab
- guselkumab
- hydrocodone
- ibritumomab tiuxetan
- idecabtagene vicleucel
- inebilizumab
- infliximab
- inotuzumab ozogamicin
- isatuximab
- ivosidenib
- ixekizumab
- lebrikizumab
- linvoseltamab
- lisocabtagene maraleucel
- loncastuximab tesirine
- lumacaftor/ivacaftor
- lymphocyte immune globulin, anti-thymocyte globulin
- meperidine
- methadone
- mitotane
- mogamulizumab
- mosunetuzumab
- mycophenolate mofetil
- mycophenolic acid
- narsoplimab
- natalizumab
- nipocalimab
- obecabtagene autoleucel
- obinutuzumab
- ocrelizumab
- ofatumumab
- oxycodone
- pacritinib
- pentobarbital
- phenobarbital
- phenytoin
- pimecrolimus topical
- pimozide
- polatuzumab vedotin
- pozelimab
- pralsetinib
- primidone
- propafenone
- rabies vaccine
- ravulizumab
- rifabutin
- rifampin
- rilonacept
- risankizumab
- rituximab
- ropeginterferon alfa-2b
- rozanolixizumab
- ruxolitinib
- ruxolitinib topical
- sarilumab
- satralizumab
- secukinumab
- sibeprenlimab
- siltuximab
- simvastatin
- sirolimus
- spesolimab
- St. John's wort
- sutimlimab
- tacrolimus
- tafasitamab
- talquetamab
- tarlatamab
- teplizumab
- tildrakizumab
- tisagenlecleucel
- tizanidine
- tocilizumab
- tofacitinib
- tralokinumab
- tranexamic acid
- ublituximab
- upadacitinib
- ustekinumab
- vaccinia immune globulin
- vedolizumab
- vilobelimab
- voclosporin
Monitor/Modify Tx
- abemaciclib
- acalabrutinib
- aflibercept
- alfentanil
- aminocaproic acid
- aminophylline
- amiodarone
- angiotensin II
- anthrax immune globulin
- anthrax vaccine
- anti-inhibitor coagulant complex
- antihemophilic factor (factor VIII)/von Willebrand factor complex
- asciminib
- asparaginase
- atidarsagene autotemcel
- avanafil
- avapritinib
- avatrombopag
- axitinib
- bazedoxifene
- bendamustine
- bevacizumab
- binimetinib
- botulism immune globulin
- brigatinib
- brolucizumab
- C1 esterase inhibitor
- cabozantinib
- caffeine citrate
- calaspargase
- capivasertib
- carfilzomib
- celecoxib
- chikungunya vaccine
- chorionic gonadotropin
- clozapine
- coagulation factor IX
- coagulation factor VIIa
- coagulation factor XIII A-subunit
- concizumab
- COVID-19 vaccine
- cytomegalovirus immune globulin
- danazol
- darbepoetin alfa
- deflazacort
- desogestrel (contraceptive)
- dexamethasone
- diclofenac
- diclofenac topical
- dienogest (contraceptive)
- diflunisal
- diphtheria/tetanus vaccine
- diphtheria/tetanus/pertussis vaccine
- disopyramide
- docetaxel
- dofetilide
- domperidone
- drospirenone (contraceptive)
- drospirenone (hormone replacement)
- ebola vaccine, live
- eltrombopag
- entrectinib
- epirubicin
- eplerenone
- epoetin alfa
- erythromycin
- estetrol (contraceptive)
- estradiol (contraceptive)
- estradiol (hormone replacement)
- estrogens, conjugated (hormone replacement)
- estrogens, esterified (hormone replacement)
- ethinyl estradiol (contraceptive)
- ethinyl estradiol (hormone replacement)
- ethynodiol (contraceptive)
- etodolac
- etonogestrel (contraceptive)
- factor XIII concentrate
- faricimab
- felodipine
- fenofibrate
- fenofibric acid
- fenoprofen
- fentanyl
- fibrinogen (human)
- finerenone
- fitusiran
- flibanserin
- flurbiprofen
- follitropin
- fruquintinib
- gepirone
- Haemophilus b vaccine
- hepatitis A vaccine
- hepatitis B immune globulin
- hepatitis B vaccine
- human papillomavirus vaccine
- ibrutinib
- ibuprofen
- immune globulin
- indomethacin
- influenza H5N1 vaccine
- influenza vaccine
- iodixanol
- iohexol
- iomeprol
- iopamidol
- iopromide
- iothalamate meglumine
- ioversol
- ivabradine
- ixabepilone
- Japanese encephalitis vaccine
- ketoprofen
- ketorolac
- lazertinib
- lemborexant
- lenalidomide
- lenvatinib
- levoketoconazole
- levonorgestrel (contraceptive)
- levonorgestrel (hormone replacement)
- lomitapide
- lonafarnib
- lovastatin
- lumateperone
- lurasidone
- lurbinectedin
- luspatercept
- lusutrombopag
- mavacamten
- meclofenamate
- medroxyprogesterone (contraceptive)
- medroxyprogesterone (hormone replacement)
- mefenamic acid
- megestrol
- meloxicam
- meningococcal vaccine
- menotropins
- methoxy polyethylene glycol-epoetin beta
- methyltestosterone
- midazolam
- mitomycin
- mobocertinib
- momelotinib
- nabumetone
- naproxen
- necitumumab
- nifedipine
- nimodipine
- nintedanib
- nisoldipine
- norelgestromin (contraceptive)
- norethindrone (contraceptive)
- norethindrone (hormone replacement)
- norgestimate (contraceptive)
- norgestrel (contraceptive)
- olaparib
- oliceridine
- ospemifene
- oxaprozin
- pazopanib
- pegaspargase
- pemigatinib
- piroxicam
- pneumococcal vaccine
- poliovirus vaccine
- pomalidomide
- ponatinib
- porfimer
- progesterone (hormone replacement)
- progesterone vaginal (hormone replacement)
- prothrombin complex concentrate (human)
- quinidine (antiarrhythmic)
- raloxifene
- ramucirumab
- ranibizumab
- red yeast rice
- respiratory syncytial virus vaccine
- Rho(D) immune globulin
- ribociclib
- romiplostim
- salsalate
- segesterone (contraceptive)
- selpercatinib
- sipuleucel-T
- sirolimus albumin-bound
- smallpox/mpox vaccine, live
- sodium tetradecyl sulfate
- sotatercept
- sufentanil
- sulindac
- tadalafil
- taletrectinib
- tamoxifen
- temsirolimus
- testosterone
- thalidomide
- theophylline
- tick-borne encephalitis vaccine
- tivozanib
- tolmetin
- tolvaptan
- toremifene
- trametinib
- tretinoin
- triazolam
- typhoid vaccine
- ubrogepant
- vadadustat
- valoctocogene roxaparvovec
- vamorolone
- vardenafil
- varicella zoster immune globulin
- venetoclax
- vinblastine
- vincristine
- vinorelbine
- von Willebrand factor
- vorinostat
- warfarin
- zanubrutinib
- ziv-aflibercept
- zopapogene imadenovec
Caution Advised
- alosetron
- avacopan
- azacitidine
- beclomethasone inhaled
- beclomethasone nasal
- belinostat
- betamethasone
- bimekizumab
- bortezomib
- bosentan
- budesonide
- budesonide inhaled
- budesonide nasal
- budesonide rectal
- busulfan
- cabazitaxel
- carboplatin
- cariprazine
- carmustine
- cenobamate
- chlorambucil
- ciclesonide
- cisplatin
- cladribine injection
- clobetasol ophthalmic
- clofarabine
- cobimetinib
- coccidioides immitis skin test antigen
- conivaptan
- copanlisib
- corticotropin
- cortisone
- cyclophosphamide
- cytarabine
- dabrafenib
- dactinomycin
- danicopan
- daridorexant
- daunorubicin
- decitabine
- dexamethasone ophthalmic
- difluprednate ophthalmic
- dihydroergotamine
- dimethyl fumarate
- diroximel fumarate
- doxorubicin
- duvelisib
- efavirenz
- elinzanetant
- elivaldogene autotemcel
- ergotamine
- eribulin
- etoposide
- etravirine
- etuvetidigene autotemcel
- fexinidazole
- fingolimod
- floxuridine
- fludarabine
- fludrocortisone
- flunisolide nasal
- fluocinolone intravitreal
- fluorometholone ophthalmic
- fluticasone furoate
- fluticasone propionate
- hydrocortisone
- hydrocortisone ophthalmic
- hydroxyurea
- icotrokinra
- idarubicin
- idelalisib
- ifosfamide
- iptacopan
- irinotecan
- leflunomide
- lifileucel
- lomustine
- lopinavir/ritonavir
- lorlatinib
- loteprednol ophthalmic
- melphalan
- mercaptopurine
- methotrexate
- methylergonovine
- methylprednisolone
- mirikizumab
- mitapivat
- mitoxantrone
- modafinil
- mometasone implant
- mometasone inhaled
- mometasone nasal
- monomethyl fumarate
- nadofaragene firadenovec intravesical
- nafcillin
- nelarabine
- oxaliplatin
- ozanimod
- paclitaxel
- palovarotene
- pegcetacoplan
- pentostatin
- pexidartinib
- pirfenidone
- pirtobrutinib
- ponesimod
- prednisolone
- prednisolone ophthalmic
- prednisone
- procarbazine
- quizartinib
- regorafenib
- relacorilant
- repotrectinib
- rifapentine
- rilzabrutinib
- roflumilast
- roflumilast topical
- romidepsin
- selinexor
- siponimod
- sirolimus topical
- sotorasib
- sulfasalazine
- teclistamab
- temozolomide
- teriflunomide
- thioguanine
- thiotepa
- topotecan
- trabectedin
- triamcinolone
- tuberculin purified protein derivative
- verapamil
- vorasidenib
- zilucoplan
Adverse Reactions .
Serious Reactions
- infection, serious
- opportunistic infection
- viral reactivation
- HBV reactivation
- herpes zoster
- thrombocytopenia
- lymphopenia
- malignancy
- non-melanoma skin CA
- pulmonary embolism
- MI, acute
- cardiovascular death risk
- hypersensitivity reaction, severe
- anaphylaxis
Common Reactions
- headache
- diarrhea
- acne
- rash
- urticaria
- folliculitis
- fever
- atopic dermatitis
- dizziness
- ALT or AST elevated
Safety/Monitoring .
Monitoring Parameters
hepatitis panel at baseline; CBC with diff at baseline, then 4wk after tx start, then periodically; LFTs, TB test at baseline, then periodically; dermatologic exams if incr. skin CA risk
Pregnancy/Lactation .
Pregnancy
Clinical Summary
weigh risk/benefit during pregnancy; inadequate human data available; possible risk of embryo-fetal toxicity and malformation based on animal data at 49x MRHD and 55x MRHD, respectively
Pregnancy Reporting
report pregnancy to Pfizer at 1-877-390-2940
Lactation
Clinical Summary
avoid breastfeeding during tx and x14h after D/C; no human data available to assess risk of infant harm, though possible drug excretion into milk based on drug properties; no human data available to assess effects on milk production
Pharmacology .
Metabolism: for ritlecitinib: liver; CYP450: 1A2, 2C8, 2C9, 3A4 substrate
Excretion: for ritlecitinib: urine 66% (4% unchanged), feces 20%; Half-life: 1.3-2.3h
Subclass: Cosmetic, Dermatologic ; JAK Inhibitors, Dermatologic ; TEC Kinase Inhibitors
Mechanism of Action
for ritlecitinib: exact mechanism of action unknown; inhibits janus-associated kinase (JAK) 3, preventing cytokine-induced STAT protein phosphorylation; inhibits tyrosine kinase expressed in hepatocellular carcinoma (TEC) kinase family, preventing immune receptor signaling
Formulary .
No Formulary Selected
Join Now to View Patient Handouts!
Create a FREE epocrates Online account to access patient medication instructions. Your patients and caregivers will appreciate you printing these friendly handouts, available in English and Spanish. Each handout addresses common concerns such as how to take the medication, and possible side effects.
Current Members: Sign In.
Pill Pictures
Join Now to View Pill Pictures!
Create a FREE epocrates Online account to access full-color images of medications within the drug monograph.
Current Members: Sign In.